Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.

Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Herzenberg LA, Herzenberg LA, Vogel SN.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4343-8. doi: 10.1073/pnas.0813411106. Epub 2009 Feb 26.

2.

Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y, Gearhart PJ, Chesko KL, Viscardi RM, Vogel SN.

J Leukoc Biol. 2011 Oct;90(4):787-97. doi: 10.1189/jlb.0111014. Epub 2011 Jul 12.

3.

Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.

Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ, Rallabhandi P, Cuesta N, Vogel SN.

J Immunol. 2006 Jun 1;176(11):6888-99.

6.

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Richard K, Mann BJ, Stocker L, Barry EM, Qin A, Cole LE, Hurley MT, Ernst RK, Michalek SM, Stein DC, Deshong P, Vogel SN.

Clin Vaccine Immunol. 2014 Feb;21(2):212-26. doi: 10.1128/CVI.00738-13. Epub 2013 Dec 18.

7.

An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.

Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.

8.

Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL.

J Infect Dis. 2012 Apr 1;205(7):1056-65. doi: 10.1093/infdis/jir620. Epub 2011 Oct 3.

9.

Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP.

Clin Vaccine Immunol. 2009 Apr;16(4):444-52. doi: 10.1128/CVI.00405-08. Epub 2009 Feb 11.

10.

Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.

Fulop M, Mastroeni P, Green M, Titball RW.

Vaccine. 2001 Aug 14;19(31):4465-72.

PMID:
11483272
12.

Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Chiavolini D, Weir S, Murphy JR, Wetzler LM.

Clin Vaccine Immunol. 2008 Sep;15(9):1322-9. doi: 10.1128/CVI.00125-08. Epub 2008 Jul 9.

13.

Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.

Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, Pechous RD, Zahrt T, Inzana TJ.

Microbiology. 2007 Sep;153(Pt 9):3141-53.

PMID:
17768257
14.
15.

Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.

Sebastian S, Pinkham JT, Lynch JG, Ross RA, Reinap B, Blalock LT, Conlan JW, Kasper DL.

Vaccine. 2009 Jan 22;27(4):597-605. doi: 10.1016/j.vaccine.2008.10.079. Epub 2008 Nov 18.

16.

A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.

Ashtekar AR, Katz J, Xu Q, Michalek SM.

PLoS One. 2012;7(11):e50460. doi: 10.1371/journal.pone.0050460. Epub 2012 Nov 28.

18.
19.

Preclinical testing of a vaccine candidate against tularemia.

Suresh RV, Ma Z, Sunagar R, Bhatty V, Banik S, Catlett SV, Gosselin EJ, Malik M, Bakshi CS.

PLoS One. 2015 Apr 21;10(4):e0124326. doi: 10.1371/journal.pone.0124326. eCollection 2015.

20.

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

Supplemental Content

Support Center